Optimistic Buy Rating for Brainstorm Cell Therapeutics as NurOwn Advances Into Enhanced Phase 3b ALS Trial
Brainstorm Cell Analyst Ratings
Brainstorm Cell Analyst Ratings
Brainstorm Cell Therapeutics (BCLI) Receives a Buy From Maxim Group
Brainstorm Cell Therapeutics (BCLI) Receives a Buy From Maxim Group
Maxim Group Adjusts Price Target on Brainstorm Cell Therapeutics to $10 From $5, Maintains Buy Rating
Analysts Offer Insights on Healthcare Companies: Cardinal Health (CAH), Brainstorm Cell Therapeutics (BCLI) and Agilon Health (AGL)
Brainstorm Cell Therapeutics (BCLI) Receives a Buy From Maxim Group
Maxim Group Remains a Buy on Brainstorm Cell Therapeutics (BCLI)
Brainstorm Cell Therapeutics (BCLI) Receives a Buy From Maxim Group